Portal pressure changes after banding or sclerotherapy for esophageal varices
Official title: The Comparative Study on the Alteration of Endoscopic Ultrasound Guided Portal Pressure Gradient in Esophageal Varices After Ligation and Sclerotherapy
Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT07253090 · Data updated 2026-11-12
This will test whether endoscopic band ligation or sclerotherapy changes portal pressure measured by endoscopic ultrasound in adults with cirrhosis and esophagogastric varices.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Second Affiliated Hospital, Zhejiang University, School of Medicine Academic / other |
| Locations | 1 site (Hangzhou) |
| Status | Recruiting |
| Started | August 18, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | November 28, 2025 |
| Trial ID | NCT07253090 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–80 with cirrhosis admitted for primary or secondary prevention of esophagogastric varices who can give informed consent and meet clotting and medication criteria are ideal candidates.
✕Probably not a fit
Patients with INR >1.5, platelets <20,000/µL, recent propranolol/carvedilol use, those outside the 18–80 age range, or those unwilling to consent are excluded and unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center interventional study will measure portal pressure using endoscopic ultrasound-guided PPG before and after endoscopic ligation or sclerotherapy in cirrhotic patients with esophagogastric varices. Eligible hospitalized adults undergoing primary or secondary prevention will receive standard endoscopic therapy and have PPG recordings taken peri-procedurally. The trial will compare pressure changes between ligation and sclerotherapy and relate findings to clinically significant portal hypertension thresholds. Key exclusions include significant coagulopathy, very low platelets, recent use of propranolol/carvedilol, and extreme age, and all procedures are done at the enrolling hospital in Hangzhou.
Why it matters
Potential benefit: If successful, this could clarify whether endoscopic therapies alter portal pressure and help clinicians choose treatments to lower bleeding risk.
How similar studies have gone: Non-selective beta-blockers and TIPS are known to reduce portal pressure, but evidence that endoscopic ligation or sclerotherapy changes portal hemodynamics is limited and EUS-guided portal pressure measurement is a relatively new technique with only preliminary validation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Cirrhotic patients admitted for primary/secondary prevention due to esophageal and gastric varices, and willing to sign the informed consent form. Exclusion Criteria: 1. Refusing to sign the informed consent form; 2. Age \< 18 years, or ≥ 81 years; 3. Coagulopathy (INR \> 1.5); 4. Markedly decreased platelets (\<20,000/μL); 5. Propranolol/carvedilol was used 24h before admission.
Where it's running
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China Recruiting
Study contacts
- Study coordinator: Meng Xue
- Email: xuemeng@zju.edu.cn
- Phone: +86 0571 87783544
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Portal hypertension with esophagogastric varices: endoscopic treatment vs. non-endoscopic care
This study tests whether endoscopic treatment helps people with portal hypertension and varices compared to those who don’t get endoscopic therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.